Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 313 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alopecia Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Aldara for the Treatment of Extensive Alopecia Areata

NCT00177021
View directory record Official record
Conditions
Alopecia Areata
Interventions
Aldara Cream 5%
Drug
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2006 · Synced Oct 21, 2026, 7:22 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240
View directory record Official record
Conditions
Alopecia Areata
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 63 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
78
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Withdrawn Phase 2 Interventional

Topical Crisaborole in Patients with Alopecia Areata

NCT04299503
View directory record Official record
Conditions
Alopecia Areata
Interventions
Crisaborole Topical Ointment, Placebo Topical Ointment
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata

NCT02018042
View directory record Official record
Conditions
Alopecia Areata
Interventions
Abatacept
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Early Phase 1 Interventional

A Clinical Comparison of FDA-Cleared Photobiomodulation Devices for the Treatment of Alopecia

NCT06748287
View directory record Official record
Conditions
Alopecia
Interventions
iGrow Hair Growth System, Capillus352, HairMax Ultima 12 Lasercomb, HairMax Laserband 82
Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 85 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 21, 2026, 7:22 PM EDT
Recruiting Phase 2Phase 3 Interventional

Phase 2/3 Efficacy and Safety of PP405 in Adult Males

NCT07819435
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
PP405 0.05% Topical Gel, Vehicle Topical Gel
Drug
Lead sponsor
Pelage Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Hot Springs, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

NCT02611804
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Diclofenac sodium, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
30
States / cities
Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Not applicable Interventional Results available

A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia

NCT05759338
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia
Interventions
Revian Red All LED cap
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 21, 2026, 7:22 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Efficacy and Safety of VDPHL01 in Males With AGA

NCT06724614
View directory record Official record
Conditions
Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions
VDPHL01, Placebo
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 21, 2026, 7:22 PM EDT
Recruiting Phase 2 Interventional

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

NCT07242638
View directory record Official record
Conditions
Atopic Dermatitis, Alopecia Areata
Interventions
Abrocitinib
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Active, not recruiting Early Phase 1 Interventional

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

NCT05416333
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia
Interventions
azelaic acid, usual medication for CCCA
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

NCT04913519
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, Placebo
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
San Diego, California • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 21, 2026, 7:22 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata

NCT01385839
View directory record Official record
Conditions
Alopecia Areata, Alopecia, Balding
Interventions
Hair transplantation, Hypodermic needle irritation
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 21, 2026, 7:22 PM EDT
Not yet recruiting Early Phase 1 Interventional

Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia

NCT03474718
View directory record Official record
Conditions
Androgenic Alopecia
Interventions
Platelet-rich Plasma Left Side, Platelet-rich Plasma Right Side
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.

NCT06360718
View directory record Official record
Conditions
Leukemia
Interventions
"Who is Luke Eemia?" Storybook
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
3 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 21, 2026, 7:22 PM EDT
Terminated Phase 1 Interventional

Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy

NCT01367990
View directory record Official record
Conditions
Alopecia, Radiodermatitis
Interventions
Norepinephrine
Drug
Lead sponsor
ProCertus BioPharm, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 21, 2026, 7:22 PM EDT
Recruiting Phase 2 Interventional

A Study of LAD603 in Adults With Alopecia Areata

NCT07311564
View directory record Official record
Conditions
Alopecia Areata
Interventions
LAD603, Placebo
Drug · Other
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Completed No phase listed Observational

A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings

NCT07200128
View directory record Official record
Conditions
Severe Alopecia Areata
Interventions
Ritlecitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

NCT02547363
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204 gel, Vehicle gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Not applicable Interventional

Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment

NCT02591355
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Autologous Platelet Rich Plasma, Saline solution injection
Device
Lead sponsor
Regen Lab SA
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair

NCT05339958
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol® Men Hair Growth Nutraceutical, Placebo Supplement
Dietary Supplement · Other
Lead sponsor
Nutraceutical Wellness Inc.
Industry
Eligibility
21 Years to 55 Years · Male only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Manhattan Beach, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

NCT01023841
View directory record Official record
Conditions
Eyelash Hypotrichosis, Alopecia Areata
Interventions
bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 21, 2026, 7:22 PM EDT
Active, not recruiting Phase 4 Interventional

A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

NCT06240351
View directory record Official record
Conditions
Frontal Fibrosing Alopecia
Interventions
Baricitinib 4 MG Oral Tablet
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 21, 2026, 7:22 PM EDT